News Dr. Reddy's Laboratories Limited

Stocks

500124

INE089A01031

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:11:09 15/06/2026 pm IST			5-day change	1st Jan Change
1,276.80 ^INR	+0.23%		+0.11%	+0.48%

09:15am	Indian shares join global rally on Gulf peace deal, oil slides	RE
08:05am	Indian shares set to join global rally on Gulf peace deal, oil slides	RE

All News

Mentions Relevance

13/06	Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States	BU
13/06	Dr. Reddy?s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States	CI
30/05	Dr Reddy Laboratories : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
20/05	Dr Reddy's launches oral semaglutide biosimilar Obeda in India	RE
19/05	R-Pharm Group of Companies and Dr. Reddy?S Laboratories Ltd. Signs Agreement to Localize Production of Toripalimab for Tumor Therapy	CI
16/05	Dr. Reddy?S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada	CI
16/05	Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada	BU
13/05	Dr. Reddy's Laboratories' Consolidated Profit Plunges in Fiscal Q4	MT
13/05	Doctor Reddy's: Fiscal Q4 Earnings Snapshot	AQ
12/05	Dr. Reddy's Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
12/05	Dr. Reddy's Laboratories Limited, Q4 2026 Earnings Call, May 12, 2026
12/05	Dr. Reddy's to Launch Generic Ozempic in Canada This Month	MT
12/05	Dr. Reddy's to Launch Generic Ozempic in Canada This Month, Bloomberg Reports	MT
12/05	India's Dr Reddy's looking to launch Semaglutide in Canada in next few days in this month	RE
12/05	Dr Reddy Laboratories : . Reddy’s Q4 & Full Year FY26 Financial Results	PU
12/05	Dr. Reddy's Laboratories Limited Approves Elevation of Sandeep Khandelwal, Global Generics India Head as Senior Management Personnel, Effective May 12, 2026	CI
12/05	Dr Reddy's got marketing authorization for generic semaglutide tablets in India from DCGI	RE
12/05	Dr. Reddy's Q4 consol net PAT 2.21 billion rupees; IBES est. 9.25 billion rupees	RE
12/05	Indian drugmaker Dr Reddy's posts quarterly profit slump	RE
12/05	Dr. Reddy's Laboratories Limited announces Annual dividend, payable on August 22, 2026	CI
30/04	Health Care Down on Mixed Earnings -- Health Care Roundup	DJ
29/04	Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic	DJ
29/04	Dr. Reddy's Laboratories Receives Health Canada Approval for Generic Semaglutide	MT
29/04	Dr Reddys Laboratories Ltd Receives Health Canada Approval For Generic Semaglutide Injection	CI
29/04	Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada	BU